{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:23:58Z","timestamp":1793384638366,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003339","name":"Spanish Scientific Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Community of Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hearing Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heares.2024.109012","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T13:07:27Z","timestamp":1713704847000},"page":"109012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Tumors of the nervous system and hearing loss: Beyond vestibular schwannomas"],"prefix":"10.1016","volume":"447","author":[{"given":"Carmen","family":"Ruiz-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Lassaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"L\u00f3pez-Larrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Varela-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Murillo-Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heares.2024.109012_bib0001","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/MAO.0b013e3181de46ae","article-title":"Predictors of vestibular schwannoma growth and clinical implications","volume":"31","author":"Agrawal","year":"2010","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0002","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/j.1471-4159.1987.tb02453.x","article-title":"Regulated galactolipid synthesis and cell surface expression in Schwann cell line D6P2T","volume":"49","author":"Bansal","year":"1987","journal-title":"J. Neurochem."},{"key":"10.1016\/j.heares.2024.109012_bib0003","doi-asserted-by":"crossref","first-page":"e80908","DOI":"10.1371\/journal.pone.0080908","article-title":"Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages","volume":"8","author":"Barros","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.heares.2024.109012_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0065-230X(08)60702-2","article-title":"Alterations in DNA methylation: a fundamental aspect of neoplasia","volume":"72","author":"Baylin","year":"1998","journal-title":"Adv. Cancer. Res."},{"key":"10.1016\/j.heares.2024.109012_bib0005","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1212\/WNL.0000000000012436","article-title":"Genotype-Phenotype correlations in neurofibromatosis and their potential clinical use","volume":"97","author":"Bettegowda","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.heares.2024.109012_bib0006","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/neuonc\/noac042","article-title":"Distinct metabolic hallmarks of WHO classified adult glioma subtypes","volume":"24","author":"Bj\u00f6rkblom","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0007","doi-asserted-by":"crossref","first-page":"9940","DOI":"10.18632\/oncotarget.24119","article-title":"CXCR4: a new player in vestibular schwannoma pathogenesis","volume":"9","author":"Breun","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.heares.2024.109012_bib0008","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s11912-023-01451-z","article-title":"Management of central and peripheral nervous system tumors in patients with neurofibromatosis","volume":"25","author":"Brown","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.heares.2024.109012_bib0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-4939-3615-1_4","article-title":"Generation of noninvasive, quantifiable, orthotopic animal models for NF2-associated schwannoma and meningioma","volume":"1427","author":"Burns","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.heares.2024.109012_bib0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/neuonc\/nor072","article-title":"AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas","volume":"13","author":"Bush","year":"2011","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0011","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra2020394","article-title":"Vestibular schwannomas","volume":"384","author":"Carlson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heares.2024.109012_bib0012","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1097\/MAO.0000000000001932","article-title":"Next generation sequencing of sporadic vestibular schwannoma: necessity of biallelic NF2 inactivation and implications of accessory non-NF2 variants","volume":"39","author":"Carlson","year":"2018","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0013","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1093\/neuros\/nyx511","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on hearing preservation outcomes in patients with sporadic vestibular schwannomas","volume":"82","author":"Carlson","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.heares.2024.109012_bib0014","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","article-title":"A timeline of tumour-associated macrophage biology","volume":"23","author":"Cassetta","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heares.2024.109012_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","article-title":"VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate","volume":"26","author":"Cay\u00e9-Thomasen","year":"2005","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076522","article-title":"Tumor microenvironment in sporadic vestibular schwannoma: a systematic, narrative review","volume":"24","author":"Cazzador","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heares.2024.109012_bib0017","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1097\/01.mlg.0000240185.14224.7d","article-title":"Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice","volume":"116","author":"Chang","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.heares.2024.109012_bib0018","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1038\/s41598-017-05769-0","article-title":"Differential NF2 gene status in sporadic vestibular schwannomas and its prognostic impact on tumour growth patterns","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heares.2024.109012_bib0019","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","article-title":"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.heares.2024.109012_bib0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.heares.2024.109012_bib0021","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41467-023-37226-0","article-title":"Cellular mechanisms of heterogeneity in NF2-mutant schwannoma","volume":"14","author":"Chiasson-MacKenzie","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heares.2024.109012_bib0022","first-page":"vdad099","article-title":"A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis","volume":"5","author":"Chiranth","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.heares.2024.109012_bib0023","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/lary.26589","article-title":"MRI surveillance of vestibular schwannomas without contrast enhancement: clinical and economic evaluation","volume":"128","author":"Coelho","year":"2018","journal-title":"Laryngoscope"},{"key":"10.1016\/j.heares.2024.109012_bib0024","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.febslet.2014.04.001","article-title":"Molecular insights into NF2\/Merlin tumor suppressor function","volume":"588","author":"Cooper","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.heares.2024.109012_bib0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MAO.0b013e31827c9fbf","article-title":"Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas","volume":"34","author":"de Vries","year":"2013","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.inat.2019.01.007","article-title":"Brainstem glioma: clinical significance and prognostic evaluation","volume":"16","author":"Deshpande","year":"2019","journal-title":"Interdisciplinary Neurosurg."},{"key":"10.1016\/j.heares.2024.109012_bib0027","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/neuonc\/nou317","article-title":"Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas","volume":"17","author":"Dewan","year":"2015","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0028","doi-asserted-by":"crossref","first-page":"572","DOI":"10.25259\/SNI_781_2021","article-title":"Cerebellopontine angle ependymoma presenting as isolated hearing loss in an elderly patient: a case report and literature review","volume":"12","author":"Dibs","year":"2021","journal-title":"Surg. Neurol. Int."},{"key":"10.1016\/j.heares.2024.109012_bib0029","doi-asserted-by":"crossref","first-page":"18599","DOI":"10.1038\/srep18599","article-title":"Secreted factors from human vestibular schwannomas can cause cochlear damage","volume":"5","author":"Dilwali","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heares.2024.109012_bib0030","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1097\/MAO.0000000000001766","article-title":"A xenograft model of vestibular schwannoma and hearing loss","volume":"39","author":"Dinh","year":"2018","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0031","first-page":"962","article-title":"Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801","volume":"138","author":"Dougherty","year":"2023","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.heares.2024.109012_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-14-0209","article-title":"Tumors: wounds that do not heal-redux","volume":"3","author":"Dvorak","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heares.2024.109012_bib0033","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/lary.27586","article-title":"Progression of hearing loss in neurofibromatosis type 2 according to genetic severity","volume":"129","author":"Emmanouil","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.heares.2024.109012_bib0034","series-title":"GeneReviews(\u00ae)","article-title":"NF2-Related Schwannomatosis","author":"Evans","year":"1993"},{"key":"10.1016\/j.heares.2024.109012_bib0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-022-03958-0","article-title":"Predictors of hearing functional outcome following surgery for cerebellopontine angle meningioma","volume":"157","author":"Fatima","year":"2022","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.heares.2024.109012_bib0036","first-page":"975","article-title":"The significance of M1 macrophage should be highlighted in peripheral nerve regeneration","volume":"38","author":"Feng","year":"2023","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.heares.2024.109012_bib0037","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","article-title":"Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2","volume":"261","author":"Ferner","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.heares.2024.109012_bib0038","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.otc.2015.02.006","article-title":"Nonschwannoma tumors of the cerebellopontine angle","volume":"48","author":"Friedmann","year":"2015","journal-title":"Otolaryngol. Clin. North Am."},{"key":"10.1016\/j.heares.2024.109012_bib0039","doi-asserted-by":"crossref","first-page":"14676","DOI":"10.1073\/pnas.1512570112","article-title":"Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model","volume":"112","author":"Gao","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.heares.2024.109012_bib0040","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/hmg\/ddy361","article-title":"A proteasome-resistant fragment of NIK mediates oncogenic NF-\u03baB signaling in schwannomas","volume":"28","author":"Gehlhausen","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.heares.2024.109012_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/ddu414","article-title":"A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation","volume":"24","author":"Gehlhausen","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.heares.2024.109012_bib0042","first-page":"96","article-title":"Profound hearing loss following surgery in pediatric patients with posterior fossa low-grade glioma","volume":"5","author":"Ghazwani","year":"2018","journal-title":"Neurooncol. Pract."},{"key":"10.1016\/j.heares.2024.109012_bib0043","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1097\/MAO.0000000000000479","article-title":"Extra-Axial ependymoma presenting as a cerebellopontine angle mass","volume":"36","author":"Gill","year":"2015","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0044","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1101\/gad.13.8.978","article-title":"Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein","volume":"13","author":"Giovannini","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.heares.2024.109012_bib0045","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","article-title":"Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2","volume":"14","author":"Giovannini","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.heares.2024.109012_bib0046","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0047","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/neuonc\/noz153","article-title":"EANO guideline on the diagnosis and treatment of vestibular schwannoma","volume":"22","author":"Goldbrunner","year":"2020","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0048","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","article-title":"A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas","volume":"133","author":"Goutagny","year":"2017","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.heares.2024.109012_bib0049","doi-asserted-by":"crossref","first-page":"fcad197","DOI":"10.1093\/braincomms\/fcad197","article-title":"The comparable tumour microenvironment in sporadic and NF2-related schwannomatosis vestibular schwannoma","volume":"5","author":"Gregory","year":"2023","journal-title":"Brain Commun."},{"key":"10.1016\/j.heares.2024.109012_bib0050","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/0008-5472.CAN-15-1144","article-title":"YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2-EGFR signaling axis","volume":"76","author":"Guerrant","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.heares.2024.109012_bib0051","article-title":"Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors","volume":"13","author":"Guo","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0052","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.neo.7900249","article-title":"Mouse models of neurofibromatosis 1 and 2","volume":"4","author":"Gutmann","year":"2002","journal-title":"Neoplasia"},{"key":"10.1016\/j.heares.2024.109012_bib0053","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cge.14310","article-title":"Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis","volume":"103","author":"Halliday","year":"2023","journal-title":"Clin. Genet."},{"key":"10.1016\/j.heares.2024.109012_bib0054","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","article-title":"Genetic severity score predicts clinical phenotype in NF2","volume":"54","author":"Halliday","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.heares.2024.109012_bib0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1227\/neu.0000000000002252","article-title":"Increased circulating chemokines and macrophage recruitment in growing vestibular schwannomas","volume":"92","author":"Hannan","year":"2023","journal-title":"Neurosurgery"},{"key":"10.1016\/j.heares.2024.109012_bib0056","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1038\/s41388-020-1374-5","article-title":"Pathomechanisms in schwannoma development and progression","volume":"39","author":"Helbing","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.heares.2024.109012_bib0057","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bpa.12125","article-title":"Schwannomas and their pathogenesis","volume":"24","author":"Hilton","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.heares.2024.109012_bib0058","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1054\/jocn.2000.0784","article-title":"The tumour suppressor protein NF2\/merlin: the puzzle continues","volume":"8","author":"Hovens","year":"2001","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.heares.2024.109012_bib0059","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-023-02268-7","article-title":"The relevance of ototoxicity induced by radiotherapy","volume":"18","author":"Huang","year":"2023","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0060","first-page":"409","article-title":"Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients","volume":"14","author":"Hung","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0061","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/MAO.0000000000001506","article-title":"Vestibular schwannoma growth with aspirin and other nonsteroidal anti-inflammatory drugs","volume":"38","author":"Hunter","year":"2017","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0062","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1007\/s10072-021-05193-3","article-title":"Efficacy of aspirin for sporadic vestibular schwannoma: a meta-analysis","volume":"42","author":"Ignacio","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.heares.2024.109012_bib0063","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/neuonc\/noac113","article-title":"Molecular biomarker-defined brain tumors: epidemiology, validity, and completeness in the United States","volume":"24","author":"Iorgulescu","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0064","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.neuchi.2018.09.003","article-title":"Neurofibromatosis type 2: hearing preservation and rehabilitation","volume":"64","author":"Jia","year":"2018","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.heares.2024.109012_bib0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S8756-3282(01)00586-5","article-title":"A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma","volume":"29","author":"John","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.heares.2024.109012_bib0066","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1101\/gad.226302","article-title":"Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse","volume":"16","author":"Kalamarides","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.heares.2024.109012_bib0067","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/MAO.0000000000001180","article-title":"Correlation between aspirin intake and reduced growth of human vestibular schwannoma: volumetric analysis","volume":"37","author":"Kandathil","year":"2016","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0068","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/neuonc\/noz051","article-title":"Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma","volume":"21","author":"Karajannis","year":"2019","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0069","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0071","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","article-title":"Phase 0 clinical trial of everolimus in patients with vestibular schwannoma or meningioma","volume":"20","author":"Karajannis","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.heares.2024.109012_bib0072","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/neuonc\/noy094","article-title":"Neurologic disorders in 4858 survivors of central nervous system tumors in childhood-an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study","volume":"21","author":"Kenborg","year":"2019","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0073","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1097\/MAO.0000000000001582","article-title":"Cochlear dysfunction is not common in human meningioma of the internal auditory canal","volume":"38","author":"Landegger","year":"2017","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0074","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.otorri.2023.10.005","article-title":"Clinical practice guideline on the management of vestibular schwannoma","volume":"75","author":"Lassaletta","year":"2024","journal-title":"Acta Otorrinolaringol. Esp."},{"key":"10.1016\/j.heares.2024.109012_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00405-014-3450-3","article-title":"Ipsilateral cochlear implantation in patients with sporadic vestibular schwannoma in the only or best hearing ear and in patients with NF2","volume":"273","author":"Lassaletta","year":"2016","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"10.1016\/j.heares.2024.109012_bib0076","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/01.mao.0000226291.42165.22","article-title":"DNA methylation of multiple genes in vestibular schwannoma: relationship with clinical and radiological findings","volume":"27","author":"Lassaletta","year":"2006","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0077","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fneur.2019.00978","article-title":"Biomarkers in vestibular schwannoma-associated hearing loss","volume":"10","author":"Lassaletta","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.heares.2024.109012_bib0078","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/MAO.0b013e318298ac79","article-title":"NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications","volume":"34","author":"Lassaletta","year":"2013","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0079","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/0194599818770413","article-title":"Natural history of sporadic vestibular schwannoma: a volumetric study of tumor growth","volume":"159","author":"Lees","year":"2018","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.heares.2024.109012_bib0080","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","article-title":"Immortalization of human normal and NF1 neurofibroma Schwann cells","volume":"96","author":"Li","year":"2016","journal-title":"Lab. Invest."},{"key":"10.1016\/j.heares.2024.109012_bib0081","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00129492-200403000-00016","article-title":"Vertigo and hearing disturbance as the first sign of a glioblastoma (World Health Organization grade IV)","volume":"25","author":"Licht","year":"2004","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0082","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/B978-0-444-52902-2.00054-0","article-title":"Neurofibromatosis type 2 (NF2): diagnosis and management","volume":"115","author":"Lloyd","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.heares.2024.109012_bib0083","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0084","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/audiolres13030031","article-title":"Hearing rehabilitation in vestibular schwannoma","volume":"13","author":"Mankekar","year":"2023","journal-title":"Audiol Res"},{"key":"10.1016\/j.heares.2024.109012_bib0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/01945998211042006","article-title":"Global incidence of sporadic vestibular schwannoma: a systematic review","volume":"167","author":"Marinelli","year":"2022","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.heares.2024.109012_bib0086","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/0194599819827812","article-title":"Impact of aspirin and other NSAID use on volumetric and linear growth in vestibular schwannoma","volume":"160","author":"Marinelli","year":"2019","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.heares.2024.109012_bib0087","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1097\/MAO.0000000000003934","article-title":"Stratifying risk of future growth among sporadic vestibular schwannomas","volume":"44","author":"Marinelli","year":"2023","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0088","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-005-9049-1","article-title":"Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients","volume":"77","author":"Marshall","year":"2006","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.heares.2024.109012_bib0089","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1101\/gad.12.8.1121","article-title":"Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors","volume":"12","author":"McClatchey","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.heares.2024.109012_bib0090","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.11.10.1253","article-title":"The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation","volume":"11","author":"McClatchey","year":"1997","journal-title":"Genes Dev."},{"key":"10.1016\/j.heares.2024.109012_bib0091","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/AUD.0000000000000883","article-title":"Diagnostic accuracy of intracochlear test electrode for acoustic nerve monitoring in vestibular schwannoma surgery","volume":"41","author":"Medina","year":"2020","journal-title":"Ear Hear."},{"key":"10.1016\/j.heares.2024.109012_bib0092","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1200\/JCO.2008.21.2738","article-title":"Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits","volume":"27","author":"Merchant","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0093","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/hum.2006.17.20","article-title":"Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2","volume":"17","author":"Messerli","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.heares.2024.109012_bib0094","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1097\/MAO.0b013e31826bed8d","article-title":"Hearing preservation in management of epidermoids of the cerebellopontine angle: CPA epidermoids and hearing preservation","volume":"33","author":"Miller","year":"2012","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamaoto.2023.3485","article-title":"Life expectancy after diagnosis of a vestibular schwannoma in patients 70 years and older","volume":"150","author":"Mistarz","year":"2024","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.heares.2024.109012_bib0096","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/MAO.0000000000003556","article-title":"Effect of AR42 in primary vestibular schwannoma cells and a xenograft model of vestibular schwannoma","volume":"43","author":"Misztal","year":"2022","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0097","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1097\/MAO.0000000000003063","article-title":"Predicting schwannoma growth in a tumor model using targeted imaging","volume":"42","author":"Morrison","year":"2021","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0098","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","article-title":"Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac","volume":"67","author":"Morrison","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.heares.2024.109012_bib0099","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/neuonc\/nox029","article-title":"The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria","volume":"19","author":"Nayak","year":"2017","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MAO.0b013e31818b6cea","article-title":"Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD\/SCID mice","volume":"30","author":"Neff","year":"2009","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0101","doi-asserted-by":"crossref","DOI":"10.1177\/2473974X211059111","article-title":"Tumor-Associated macrophages in vestibular schwannoma and relationship to hearing","volume":"5","author":"Nisenbaum","year":"2021","journal-title":"OTO Open"},{"key":"10.1016\/j.heares.2024.109012_bib0102","first-page":"471","article-title":"A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2","volume":"6","author":"Petrilli","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.heares.2024.109012_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1033185","article-title":"Neuropsychological monitoring of cognitive function and ICF-based mental components in patients with malignant brain tumours","volume":"14","author":"Pilarska","year":"2023","journal-title":"Front. Psychol."},{"key":"10.1016\/j.heares.2024.109012_bib0104","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0105","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac209.330","article-title":"CTNI-65. INTUITT-NF2, an adaptive platform-basket trial for neurofibromatosis 2 patients with progressive tumors: interim results of the brigatinib treatment arm","volume":"24","author":"Plotkin","year":"2022","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.heares.2024.109012_bib0106","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/neuonc\/noad066","article-title":"Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma","volume":"25","author":"Plotkin","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.heares.2024.109012_bib0107","first-page":"96","article-title":"CTNI-80. INTUITT-NF2, AN ADAPTIVE PLATFORM-BASKET TRIAL FOR NF2-RELATED SCHWANNOMATOSIS PATIENTS WITH PROGRESSIVE SCHWANNOMAS, MENINGIOMAS, AND EPENDYMOMAS: PRIMARY OUTCOME OF THE BRIGATINIB TREATMENT ARM","volume":"25","author":"Plotkin","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.heares.2024.109012_bib0108","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase ii and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis Type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","article-title":"Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma","volume":"93","author":"Plotkin","year":"2009","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.heares.2024.109012_bib0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heares.2024.109012_bib0111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40136-018-0186-4","article-title":"The Role of Tumor Necrosis Factor Alpha (TNF\u03b1)in Hearing Loss and Vestibular Schwannomas","volume":"6","author":"Ren","year":"2018","journal-title":"Curr. Otorhinolaryngol. Rep."},{"key":"10.1016\/j.heares.2024.109012_bib0112","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/j.1460-2075.1988.tb02990.x","article-title":"Ras-mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation","volume":"7","author":"Ridley","year":"1988","journal-title":"EMBO J."},{"key":"10.1016\/j.heares.2024.109012_bib0113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000331394","article-title":"What is the site of origin of cochleovestibular schwannomas?","volume":"17","author":"Roosli","year":"2012","journal-title":"Audiol. Neurootol."},{"key":"10.1016\/j.heares.2024.109012_bib0114","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s11912-022-01260-w","article-title":"Ependymoma: evaluation and management updates","volume":"24","author":"Rud\u00e0","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.heares.2024.109012_bib0115","doi-asserted-by":"crossref","first-page":"e27063","DOI":"10.1002\/pbc.27063","article-title":"Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis","volume":"65","author":"Sadighi","year":"2018","journal-title":"Pediatr. Blood. Cancer"},{"key":"10.1016\/j.heares.2024.109012_bib0116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/jmedgenet-2020-107022","article-title":"Sporadic vestibular schwannoma: a molecular testing summary","volume":"58","author":"Sadler","year":"2021","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.heares.2024.109012_bib0117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40001-023-01011-y","article-title":"The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis","volume":"28","author":"Salari","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.heares.2024.109012_bib0118","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5152\/iao.2018.4929","article-title":"Contemporary molecular biology of sporadic vestibular schwannomas: a systematic review and clinical implications","volume":"14","author":"Sass","year":"2018","journal-title":"J. Int. Adv. Otol."},{"key":"10.1016\/j.heares.2024.109012_bib0119","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nn.3348","article-title":"Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy","volume":"16","author":"Schulz","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.heares.2024.109012_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2021.103148","article-title":"Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: a systematic review and meta-analysis","volume":"42","author":"Shi","year":"2021","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.heares.2024.109012_bib0121","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00129492-200606000-00018","article-title":"The natural history of vestibular schwannoma","volume":"27","author":"Stangerup","year":"2006","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.heares.2024.109012_bib0122","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noab195.026","article-title":"Functional neurological disorders in patients with brain tumours","volume":"23","author":"Toh","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.heares.2024.109012_bib0123","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00234-009-0529-4","article-title":"Follow-up assessment of vestibular schwannomas: volume quantification versus two-dimensional measurements","volume":"51","author":"van de Langenberg","year":"2009","journal-title":"Neuroradiology"},{"key":"10.1016\/j.heares.2024.109012_bib0124","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1093\/neuros\/nyx516","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on emerging therapies for the treatment of patients with vestibular schwannomas","volume":"82","author":"Van Gompel","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.heares.2024.109012_bib0125","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/0194599812447766","article-title":"Three-dimensional segmented volumetric analysis of sporadic vestibular schwannomas: comparison of segmented and linear measurements","volume":"147","author":"Walz","year":"2012","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.heares.2024.109012_bib0126","first-page":"vdad123","article-title":"Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients","volume":"5","author":"Webb","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.heares.2024.109012_bib0127","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.otc.2023.02.013","article-title":"Targeted therapies in the treatment of vestibular schwannomas: current state and new horizons","volume":"56","author":"Welling","year":"2023","journal-title":"Otolaryngol. Clin. North Am."},{"key":"10.1016\/j.heares.2024.109012_bib0128","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","article-title":"Life expectancy in hereditary cancer predisposing diseases: an observational study","volume":"49","author":"Wilding","year":"2012","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.heares.2024.109012_bib0129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0035-1571166","article-title":"Hearing outcomes after middle fossa or retrosigmoid craniotomy for vestibular schwannoma tumors","volume":"77","author":"Wilkinson","year":"2016","journal-title":"J. Neurol. Surg. B Skull Base"},{"key":"10.1016\/j.heares.2024.109012_bib0130","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","article-title":"Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors","volume":"70","author":"Wong","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.heares.2024.109012_bib0131","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00401-003-0723-0","article-title":"Characterization of newly established tumor lines from a spontaneous malignant schwannoma in F344 rats: nerve growth factor production, growth inhibition by transforming growth factor-beta1, and macrophage-like phenotype expression","volume":"106","author":"Yamate","year":"2003","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.heares.2024.109012_bib0132","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/MAO.0000000000001085","article-title":"Primary epidermoid tumors of the cerebellopontine angle: a review of 47 cases","volume":"37","author":"Yawn","year":"2016","journal-title":"Otol. Neurotol."}],"container-title":["Hearing Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378595524000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378595524000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:21:43Z","timestamp":1721089303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378595524000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":132,"alternative-id":["S0378595524000650"],"URL":"https:\/\/doi.org\/10.1016\/j.heares.2024.109012","relation":{},"ISSN":["0378-5955"],"issn-type":[{"value":"0378-5955","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumors of the nervous system and hearing loss: Beyond vestibular schwannomas","name":"articletitle","label":"Article Title"},{"value":"Hearing Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heares.2024.109012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109012"}}